Actively Recruiting
Evaluating the Safety and Effectiveness of VV-14295 Gene Therapy for Adults Aged 55 to 80 with Geographic Atrophy from Age-related Macular Degeneration
Led by Kriya Therapeutics, Inc. · Updated on 2026-08-10
62
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to assess the safety, tolerability, and effectiveness of KRIYA-825 VV-14295 in adults aged 55 to 80 with geographic atrophy GA caused by age-related macular degeneration AMD. The study focuses on how well the treatment can slow the growth of GA lesions in the treated eye. It is a Phase 12, first-in-human trial sponsored by Kriya Therapeutics, Inc., designed to explore these effects using a genetic therapy delivered via a suprachoroidal injection. Participants will receive a single dose of VV-14295 as a suprachoroidal injection using the Everads Injector. The study includes several parts with varying doses low dose, high dose, and doses determined from earlier parts of the study. Alongside the gene therapy injection, participants will take oral prednisone and use difluprednate eye drops before and after dosing to reduce inflammation. After several weeks, they will switch to prednisolone acetate eye drops. This treatment process is followed by a 12-month post-treatment observation period. During the study, participants will undergo regular eye exams and imaging tests such as optical coherence tomography OCT and fundus autofluorescence FAF to monitor GA progression. Visual functions will be assessed using best-corrected visual acuity BCVA, low luminance visual acuity LLVA, and microperimetry at 3, 6, and 12 months. Safety evaluations include monitoring for adverse events, laboratory tests, vital signs, electrocardiograms ECGs, and eye health assessments throughout 12 months. The expression of the VV-14295 transgene, immune responses, and vector shedding will also be tracked to understand treatment effects and safety.
CONDITIONS
Brief Title
A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration
Research Team
V
VP, Medical Affairs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here